IMMUNO-ONCOLOGY XCHANGE
EUROPE 2023
Zurich, November 21

Welcome to hubXchange’s Europe Immuno-Oncology Xchange 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing immuno-oncology therapies, through a series of roundtable discussions.
Discussion topics will cover Immune Biomarkers, Translational Research, Clinical Development, Combination Strategies and Next-Generation Therapies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10 – 8152 Opfikon, Switzerland

SNAPSHOTS OF DISCUSSION TOPICS

Track 1: Immune Biomarkers

Predictive biomarkers for IO treatment used in clinical practice now and in the future
The rise of spatial omics technologies and their potential for new biomarker discovery

Track 2: Translational Research

Translational strategies to develop clinically safe and effective immune cell engagers
How to select the right translational screening model to monitor IO agents

Track 3: Clinical Development

Early signals of efficacy, biomarkers and confidence in early clinical I/O trials
How to maximize clinical success: Patient selection strategies beyond target expression

Track 4: Cellular Therapies

Exploring different cellular modalities
TME-targeting combinations – improving efficacy

Track 5: Next-Generation Therapies

Using next-gen multi-specific antibodies for the treatment of solid tumors
Antibody discovery for ADCs and other therapeutic modalities

Full Xchange Agenda

Click on each track for detailed agenda

Immune Biomarkers

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote Presentation

9:05 – 10:05

Predictive biomarkers for IO treatment used in clinical practice now and in the future

Serafino Pantano, Head of Clinical Biomarker Development, ADC Therapeutics

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:00 – 15:30

Poster Session

15:35 – 16:35

The rise of spatial omics technologies and their potential for new biomarker discovery

16:35 – 17:35

Evening Drinks Reception

Translational Research

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote Presentation:

9:05 – 10:05

Translational strategies to develop clinically safe and effective immune cell engagers

Laura Von Schantz, VP Discovery, Alligator Bioscience AB

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:00 – 15:30

Poster Session

15:35 – 16:35

Selecting humanized mouse models for efficacy studies in immuno-oncology

Choice of cell-lined derived xenograft (CDX) and patient-derived xenograft(PDX) models;
Immune cell composition;
Immunological mismatch.

Japar Shamshiev, Chief Scientific Officer, IOME Bio

Dr. Japar Shamshiev, the CSO at IOME Bio, is an immunology scientist with a medical background. Japar has over 20 years of experience in immunology and drug discovery, covering a range of therapeutic areas, including oncology and inflammatory diseases.
In his previous roles, Japar led the teams to develop various antibody formats. His team discovered six antibody-based drug candidates and transitioned from discovery through the clinical phases. At CellMedica, Japar led the R&D team to refine the antibody platform for developing three CAR T cell therapy products, with one of them reaching investigational new drug (IND)-enabling studies.
Japar holds six patents and is a co-author of 28 scientific peer-reviewed publications.

16:35– 17:35

Evening Drinks Reception

Clinical Development

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote Presentation:

9:05 – 10:05

Regulatory and market access evolution and impact on fast-to-market development strategies

FDA recent FDORA guidances and IRA access changes are re-shaping development priorities
Other agencies are also evolving and changing focus (i.e orphan drugs in Europe)
Benefit:risk assessment of new products needs to adapt and evolve
Changes have impact on NPV and other measures
How do we adapt ?

Ferdinando E. Vegni, Vice President, Worldwide Patient Safety, Head of Haematology and Cell Therapy, Bristol Myers Squibb

Developing and making new medicines available to patients is a fulfilling ethical and professional aim I share with many colleagues in the pharmaceutical biotech industry. A passionate and enthusiastic leader of successful teams, I strive to improve people’s lives, wisely spending investor’s money in developing and marketing high benefit:risk new treatments. A physician, epidemiologist and committed drug developer, I have worked in clinical development, pharmacovigilance, business development and corporate strategy for almost 30 years, with roles of increasing responsibility at the LSHTM, Pfizer, Celgene and now BMS. I share with my wife the joy and fun of four kids.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:00 – 15:30

Poster Session

15:30 – 16:35

Early signals of efficacy, biomarkers and confidence in early clinical I/O trials (tbc)

16:35– 17:35

Evening Drinks Reception

Cell Therapies

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote Presentation:

9:05 – 10:05

Expanding the scope of cell therapies

New indications
Earlier lines of treatment
Improving access

Ozlem Anak, VP, Global Program Head, Novartis

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:25 – 13:55

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:00 – 15:30

Poster Session

15:35 – 16:35

TME-targeting combinations – improving efficacy

In what way can we gain synergies from combinations of cell therapies and TME-targeting agents?
What are the expected benefits of combination of T-cell therapies with anti-PD1 agents?
What is the best way to evaluate rationale and MoA preclinically to support clinical studies?

Joe Sanderson, Senior Director Preclinical Research, Adaptimmune

Joe Sanderson has worked at Adaptimmune for 11 years, during which time he has led the nonclinical development of multiple TCR-based cell therapy products, including the lead product afamitresgene autoleucel, a MAGE-A4 targeting product currently in the process of seeking marketing approval for the treatment of synovial sarcoma. He currently leads the Preclinical Research department, which is responsible for all nonclinical development of novel autologous and allogeneic products.

16:35– 17:35

Evening Drinks Reception

Next-Generation Therapies

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote Presentation:

9:05 – 10:05

Overcoming resistance of poorly sensitive tumors to immunotherapy through orthogonal approaches

Can we restore immune fitness with trained immunity
What role do multi-specific antibodies play
How important is the spatial and temporal sequence of combination approaches
Contribution of mRNA based immunotherapies to overcoming resistance

Livija Deban, Chief Scientific Officer, Prokarium

Livija leads the strategic and operational development of Prokarium’s immuno-oncology portfolio, aimed at developing Living Cures for difficult-to-treat cancers, leveraging the convergence of synthetic biology and immunology. Prior to joining Prokarium, Livija headed the lead selection and immuno-oncology R&D at Oxford BioTherapeutics where she focused on the target discovery and the development of immunomodulatory antibodies for cancer treatment. Livija conducted her academic research at Cancer Research UK and holds a PhD in Basic and Applied Immunology.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:00 – 15:30

Poster Session

15:35 – 16:35

Antibody discovery for ADCs and other therapeutic modalities

16:35– 17:35

Evening Drinks Reception

IMMUNO-ONCOLOGY XCHANGE
EUROPE 2023
Zurich, November 21